

Silvia Zibellini

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3126717/publications.pdf>

Version: 2024-02-01

51
papers

2,093
citations

394421

19
h-index

265206

42
g-index

51
all docs

51
docs citations

51
times ranked

3125
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical significance of somatic mutation in unexplained blood cytopenia. <i>Blood</i> , 2017, 129, 3371-3378.	1.4	379
2	Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenström's macroglobulinemia and related lymphoid neoplasms. <i>Blood</i> , 2013, 121, 2522-2528.	1.4	290
3	Integrating clinical features and genetic lesions in the risk assessment of patients with chronic myelomonocytic leukemia. <i>Blood</i> , 2016, 128, 1408-1417.	1.4	249
4	Clinical Effects of Driver Somatic Mutations on the Outcomes of Patients With Myelodysplastic Syndromes Treated With Allogeneic Hematopoietic Stem-Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2016, 34, 3627-3637.	1.6	204
5	The BRAF V600E mutation in hairy cell leukemia and other mature B-cell neoplasms. <i>Blood</i> , 2012, 119, 188-191.	1.4	150
6	Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. <i>Haematologica</i> , 2010, 95, 1792-1796.	3.5	91
7	Pattern of somatic mutations in patients with Waldenström macroglobulinemia or IgM monoclonal gammopathy of undetermined significance. <i>Haematologica</i> , 2017, 102, 2077-2085.	3.5	90
8	Constant activation of the RAF-MEK-ERK pathway as a diagnostic and therapeutic target in hairy cell leukemia. <i>Haematologica</i> , 2013, 98, 635-639.	3.5	75
9	Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. <i>Haematologica</i> , 2011, 96, 454-458.	3.5	65
10	Relationship between clone metrics and clinical outcome in clonal cytopenia. <i>Blood</i> , 2021, 138, 965-976.	1.4	58
11	MYD88 (L265P) mutation is an independent risk factor for progression in patients with IgM monoclonal gammopathy of undetermined significance. <i>Blood</i> , 2013, 122, 2284-2285.	1.4	56
12	CpG Oligonucleotide Combined with Interleukin-2 Reveals Unexpected Chromosomal Lesions In B-CLL. <i>Blood</i> , 2010, 116, 2411-2411.	1.4	44
13	Rare variants in Toll-like receptor 7 results in functional impairment and downregulation of cytokine-mediated signaling in COVID-19 patients. <i>Genes and Immunity</i> , 2022, 23, 51-56.	4.1	41
14	Clues to pathogenesis of Waldenström macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance provided by analysis of immunoglobulin heavy chain gene rearrangement and clustering of B-cell receptors. <i>Leukemia and Lymphoma</i> , 2013, 54, 2485-2489.	1.3	31
15	Splenic marginal zone lymphoma: Clinical clustering of immunoglobulin heavy chain repertoires. <i>Blood Cells, Molecules, and Diseases</i> , 2009, 42, 286-291.	1.4	30
16	Ruxolitinib treatment and risk of B-cell lymphomas in myeloproliferative neoplasms. <i>American Journal of Hematology</i> , 2019, 94, E185-E188.	4.1	26
17	Distinctive Clinical and Histological Features of Waldenström's Macroglobulinemia and Splenic Marginal Zone Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2011, 11, 103-105.	0.4	22
18	High-resolution genome-wide array comparative genomic hybridization in splenic marginal zone B-cell lymphoma. <i>Human Pathology</i> , 2009, 40, 1628-1637.	2.0	21

#	ARTICLE	IF	CITATIONS
19	Immunogenetics features and genomic lesions in splenic marginal zone lymphoma. <i>British Journal of Haematology</i> , 2010, 151, 435-439.	2.5	20
20	Impact of B-cell count and imaging screening in cMBL: any need to revise the current guidelines?. <i>Leukemia</i> , 2012, 26, 1703-1707.	7.2	20
21	Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network. <i>American Journal of Hematology</i> , 2019, 94, 1193-1199.	4.1	18
22	MYD88L265P Detection in IgM Monoclonal Gammopathies: Methodological Considerations for Routine Implementation. <i>Diagnostics</i> , 2021, 11, 779.	2.6	14
23	A risk stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders. <i>British Journal of Haematology</i> , 2019, 187, 441-446.	2.5	13
24	Chronic lymphocytic leukemia with del13q14 as the sole abnormality: dynamic prognostic estimate by interphase FISH. <i>Hematological Oncology</i> , 2013, 31, 136-142.	1.7	12
25	JAK inhibitors and risk of B-cell lymphomas. <i>Blood</i> , 2019, 133, 2251-2253.	1.4	12
26	High Resolution Array-CGH in Splenic Marginal Zone B-Cell Lymphoma: Correlation of Copy Number Imbalances with HCV Status and Prognostic Categories.. <i>Blood</i> , 2007, 110, 2620-2620.	1.4	8
27	Targeted next-generation sequencing reveals molecular heterogeneity in non-chronic lymphocytic leukemia clonal B-cell lymphocytosis. <i>Hematological Oncology</i> , 2020, 38, 689-697.	1.7	7
28	Mutational and immunogenetic landscape of HCV-associated B-cell lymphoproliferative disorders. <i>American Journal of Hematology</i> , 2021, 96, E210-E214.	4.1	7
29	Chronic-phase chronic myeloid leukemia: Not always a reassuring diagnosis. <i>Leukemia Research Reports</i> , 2015, 4, 45-46.	0.4	6
30	Somatic Mutations of ASXL1, RUNX1 and SETBP1 Improve Prognostic Stratification of Patients with Chronic Myelomonocytic Leukemia. <i>Blood</i> , 2014, 124, 1915-1915.	1.4	6
31	HLA typing and VH gene rearrangement analysis in a family with hairy cell leukaemia. <i>Leukemia and Lymphoma</i> , 2007, 48, 805-807.	1.3	5
32	CLLU1 expression distinguishes chronic lymphocytic leukemia from other mature B-cell neoplasms. <i>Leukemia Research</i> , 2012, 36, 1204-1207.	0.8	4
33	An Insidious Presentation of Splenic Marginal Zone Lymphoma. <i>Clinical Lymphoma and Myeloma</i> , 2007, 7, 432-433.	1.4	3
34	Development of a Richter syndrome with a monoclonal component from a true B-cell chronic lymphocytic leukemia (B-CLL) treated with fludarabine. <i>Annals of Hematology</i> , 2007, 86, 619-622.	1.8	3
35	IGHV Unmutated Status Influences Outcome More Than IGHV1-69 Gene Usage Per Se in Patients With Chronic Lymphocytic Leukemia. <i>Clinical Lymphoma and Myeloma</i> , 2009, 9, 390-393.	1.4	3
36	Enrichment of Double RUNX1 Mutations in Acute Leukemias of Ambiguous Lineage. <i>Frontiers in Oncology</i> , 2021, 11, 726637.	2.8	3

#	ARTICLE	IF	CITATIONS
37	Targeted Next Generation Sequencing Identifies Novel Genetic Mutations in Patients with Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma or IgM-Monoclonal Gammopathies of Undetermined Significance. <i>Blood</i> , 2016, 128, 2928-2928.	1.4	2
38	Biological markers and prognostic scoring systems in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2009, 147, 402-404.	2.5	1
39	Splenic Marginal Zone B-Cell Lymphoma: Clinical Clustering of Immunoglobulin Heavy Chain Repertoires.. <i>Blood</i> , 2008, 112, 1775-1775.	1.4	1
40	The BRAF V600E Mutation in Hairy Cell Leukemia and Other Mature B-Cell Neoplasms. <i>Blood</i> , 2011, 118, 262-262.	1.4	1
41	Somatic Mutations Are Frequently Detected in Chronic Myeloid Leukemia in Chronic Phase and Do Not Affect Response to Tyrosine-Kinase Inhibitors. <i>Blood</i> , 2016, 128, 1117-1117.	1.4	1
42	Prevalence and Clinical Significance of the MYD88 (L265P) Somatic Mutation in Patients with Waldenstrom's Macroglobulinemia, IgM-Monoclonal Gammopathy of Undetermined Significance or Other Mature B-Cell Neoplasms.. <i>Blood</i> , 2012, 120, 2667-2667.	1.4	1
43	Systemic mastocytosis and lymphoplasmacytic lymphoma: an unusual and intriguing form of SM-AHN. <i>Leukemia and Lymphoma</i> , 2021, 62, 1782-1785.	1.3	0
44	Evolution of a True B-Cell Chronic Lymphocytic Leukaemia (B-CLL) in a Diffuse Immunocytoma after Treatment with Fludarabine.. <i>Blood</i> , 2005, 106, 4973-4973.	1.4	0
45	Stereotyped Patterns of HCDR3 Sequences in Splenic Marginal Zone B-Cell Lymphoma (SMZL): SMZL-Biased Subsets Are Associated with a Worse Outcome.. <i>Blood</i> , 2009, 114, 760-760.	1.4	0
46	Constant Activation of the RAF-MEK-ERK Pathway As a Diagnostic and Therapeutic Target in Hairy Cell Leukemia.. <i>Blood</i> , 2012, 120, 2657-2657.	1.4	0
47	Incidence and Clinical Significance of SF3B1 Somatic Mutation in Chronic Lymphocytic Leukemia.. <i>Blood</i> , 2012, 120, 2881-2881.	1.4	0
48	Hierarchical Clustering of B-Cell Receptor Structures in Splenic Marginal Zone Lymphoma. <i>Blood</i> , 2012, 120, 1585-1585.	1.4	0
49	Efficacy and Toxicity of Nucleoside Analogs in Patients with Hairy Cell Leukemia Treated Outside Clinical Trials. <i>Blood</i> , 2015, 126, 5084-5084.	1.4	0
50	Driver Somatic Mutations and Transplantation Decision Making in Patients with Myelodysplastic Syndrome. <i>Blood</i> , 2016, 128, 53-53.	1.4	0
51	Haematological malignancies in relatives of patients affected with myeloproliferative neoplasms. <i>EJHaem</i> , 0, , .	1.0	0